Epidemiological analysis and assessment of the demand for pharmacotherapeutic monitoring of patients with thyroid cancer undergoing thyroidectomy





Hypocalcemia; Adherence; Pharmaceutical care.


Thyroid cancer is the most common endocrine neoplasm in the world, with studies that have shown overdiagnosis and a real increase in advanced stages, where treatment can bring some complications to the patient. The aim of the study was to describe the epidemiological profile and assess, based on complications such as hypocalcemia, the need for pharmacotherapeutic follow-up. A retrospective observational study was carried out that evaluated the medical records, prescriptions and laboratory tests of 35 patients who underwent thyroidectomy for neoplasms in the first half of 2020. There was a prevalence of the diagnosis in females of 88.6%. The average age was 49.8 years; 60% of patients had comorbidities; the most prevalent histopathological diagnosis of thyroid cancer was papillary carcinoma with 62.1%; and, after the surgical approach, serum calcium was measured in the first 24 hours, with a rate of 48.5% of patients without an electronic medical record requesting exams. Most patients were discharged with a prescription of calcium (94%) and calcitriol (68%) for replacement, and 68.5% had outpatient medical follow-up. It is essential to evaluate the correct dosages of calcium and calcitriol due to hypokalemia, and a suggestion to the service is pharmacotherapeutic follow-up by the pharmacist to assess adherence to treatment and guidance on the correct use of medications.


Abdulsalim, S., Unnikrishnan, M. K., Manu, M. K., Alrasheedy, A. A., Godman, B., & Morisky, D. E. (2018). Structured pharmacist-led intervention programme to improve medication adherence in COPD patients: a randomized controlled study. Research in Social and Administrative Pharmacy, 14(10), 909-914.

Allemeyer, E. H., Kossow, M. S., Riemann, B., & Hoffmann, M. W. (2019). Ambulante Versorgungsqualität für den permanenten postoperativen Hypoparathyreoidismus. DMW-Deutsche Medizinische Wochenschrift, 144 (21), e130-e137.

Bumber, B., Potroško, V., Vugrinec, O., Ferenčaković, M., & Gršić, K. (2020). Hypocalcemia After Completion Thyroidectomy for Papillary Thyroid Carcinoma. Acta Clínica Croatica, 59 (Supplement 1), 136-144.

Carvalho, M., & Almeida, I. F. (2022). The Role of Pharmaceutical Compounding in Promoting Medication Adherence. Pharmaceuticals, 15(9), 1091.

Chadwick, D., Kinsman, R., & Walton, P. K. H. (2017). The British Association of Endocrine & Thyroid Surgeons: Fourth National Audit Report. 1-184.

Falch, C., Hornig, J., Senne, M., Braun, M., Konigsrainer, A., Kirschniak, A., & Muller, S. (2018). Factors predicting hypocalcemia after total thyroidectomy - A retrospective cohort analysis. International journal of surgery (London, England), 55, 46–50. https://doi.org/10.1016/j.ijsu.2018.05.014.

Instituto Nacional de Câncer - INCA (2022). Câncer de tireoide. https://www.gov.br/inca/pt-br/assuntos/cancer/tipos/tireoide.

Kallio, S. E., Kiiski, A., Airaksinen, M. S., Mäntylä, A. T., Kumpusalo‐Vauhkonen, A. E., Järvensivu, T. P., & Pohjanoksa‐Mäntylä, M. K. (2018). Community pharmacists' contribution to medication reviews for older adults: a systematic review. Journal of the American Geriatrics Society, 66(8), 1613-1620.

Karadaghy, O. A., Kallogjeri, D., & Piccirillo, J. F. (2017). Development of a new clinical severity staging system for patients with nonmetastatic papillary thyroid carcinoma. JAMA otolaryngology–head & neck surgery, 143 (12), 1173-1180.

Kitahara, C. M, Sosa, J. A., & Shiels M. S. (2020) Influence of Nomenclature Changes on Trends in Papillary Thyroid Cancer Incidence in the United States, 2000 to 2017. J Clin Endocrinol Metab. Dec 1;105(12):e 4823–30. 10.1210/clinem/dgaa690.

Kitahara, C. M., & Schneider, A. B. (2022). Epidemiology of Thyroid Cancer. Cancer epidemiology, biomarkers & prevention 31(7), 1284–1297. https://doi.org/10.1158/1055-9965.EPI-21-1440.

Kitahara, C. M., & Sosa, J. A. (2016). The changing incidence of thyroid cancer. Nat Rev Endocrinol 12(11), 646–653. https://doi.org/10.1038/nrendo.2016.110.

Lee, M., Powers, A. E., Morris, L. G. T., & Marti, J. L. (2020) Reversal in Thyroid Cancer Incidence Trends in the United States, 2000–2017 . Thyroid. 30(8), 1226–1227. 10.1089/thy.2020.0321.

Lee, Y. K., Hong, N., Park, S. H., Shin, D. Y., Lee, C. R., Kang, S. W., Jeong J. J., Nam K. H., Chung W. Y., & Lee, E. J. (2019). The relationship of comorbidities to mortality and cause of death in patients with differentiated thyroid carcinoma. Scientific reports, 9(1), 1-10.

Li, M., Dal Maso, L., & Vaccarella, S. (2020). Global trends in thyroid cancer incidence and the impact of overdiagnosis. Diabetes Endocrinol. 8(6):468-470. 10.1016/S2213-8587(20)30115-7.

Lim, H., Devesa, S. S., Sosa, J. A., Check, D., & Kitahara, C. M. (2017). Trends in Thyroid Cancer Incidence and Mortality in the United States, 1974-2013. JAMA. 317(13):1338-1348. 10.1001/jama.2017.2719.

Presley, B., Groot, W., & Pavlova, M. (2019). Pharmacy-led interventions to improve medication adherence among adults with diabetes: a systematic review and meta-analysis. Research in Social and Administrative Pharmacy, 15(9), 1057-1067.

Porter, A., & Wong, D. J. (2021). Perspectives on the treatment of advanced thyroid cancer: approved therapies, resistance mechanisms, and future directions. Frontiers in Oncology, 10, 592202. 1-7.

Pstrąg, N., Ziemnicka, K., Bluyssen, H., & Wesoły, J. (2018). Thyroid cancers of follicular origin in a genomic light: detailed overview of common and unique molecular marker candidates. Molecular Cancer, 17 (1), 1-17.

Renfro, C. P., Ferreri, S., Barber, T. G., & Foley, S. (2018). Development of a communication strategy to increase interprofessional collaboration in the outpatient setting. Pharmacy, 6(1), 4.

Seib, C. D., & Sosa, J. A. (2019). Evolução da compreensão da epidemiologia do câncer de tireoide. Endocrinology and Metabolism Clinics, 48 (1), 23-35.

Sitges Serra A. (2021). Etiology and Diagnosis of Permanent Hypoparathyroidism after Total Thyroidectomy. Journal of clinical medicine, 10(3), 543. https://doi.org/10.3390/jcm10030543.

Sitges Serra A., Gómez, J., Barczynski, M., Lorente-Poch, L., Iacobone, M., & Sancho, J. (2017). A nomogram to predict the likelihood of permanent hypoparathyroidism after total thyroidectomy based on delayed serum calcium and iPTH measurements. Gland Surgery, 6(Suppl 1), S11.

Su, D., Xia, F., Huang, W., Zhang, Z., Bai, N., Wang, D., Liao, X., & Li, X. (2021). Short-term recovery in patients suffering hypoparathyroid after thyroidectomy: a case control study. BMC surgery, 21(1), 204. https://doi.org/10.1186/s12893-021-01173-8.

Verma, A. P., Sharan, R., Manikantan, K., & Jain, P. (2020). Risk of hypocalcemia and the need to augment calcium supplementation after total thyroidectomy. Indian Journal of Surgical Oncology, 1-4.

Villarroya Marquina, I., Sancho, J., Lorente Poch, L., Gallego Otaegui, L., & Sitges Serra, A. (2018). Time to parathyroid function recovery in patients with protracted hypoparathyroidism after total thyroidectomy. European Journal of Endocrinology, 178(1), 103-111.



How to Cite

SILVA, H. A. .; FRANÇA , F. A. .; FERREIRA, M. L. de O. .; GONÇALVES, H. C. B. . Epidemiological analysis and assessment of the demand for pharmacotherapeutic monitoring of patients with thyroid cancer undergoing thyroidectomy. Research, Society and Development, [S. l.], v. 12, n. 2, p. e27612240206, 2023. DOI: 10.33448/rsd-v12i2.40206. Disponível em: https://rsdjournal.org/index.php/rsd/article/view/40206. Acesso em: 7 jun. 2023.



Health Sciences